Klenk Jeffrey P. 4
4 · TRAVELERS COMPANIES, INC. · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Travelers (TRV) EVP Jeffrey P. Klenk Exercises Options, Sells Shares
What Happened
Jeffrey P. Klenk, Executive Vice President and President, Bond & Specialty Insurance at Travelers (TRV), exercised stock options and immediately sold the resulting shares on Jan 23, 2026. He exercised 4,912 options at $140.85 ($691,855) and 11,800 options at $132.58 ($1,564,444), acquiring a total of 16,712 shares for a combined exercise cost of $2,256,299. Those 16,712 shares were sold in the open market at a weighted average price of $279.77 for total proceeds of $4,675,593 (net pre-tax proceeds ≈ $2,419,294).
Key Details
- Transaction date: January 23, 2026.
- Exercises (code M): 4,912 shares @ $140.85 (acquired for $691,855) and 11,800 shares @ $132.58 (acquired for $1,564,444).
- Sale (code S): 16,712 shares sold in the open market @ weighted avg $279.77 for $4,675,593. Footnote F1 notes sale prices ranged $279.60–$280.25; the filer will provide a breakdown on request.
- Two derivative-disposition lines at $0.00 reflect the conversion/closing out of the derivative instruments as part of the exercise.
- Shares owned after the transactions: not specified in the provided filing details.
- Filing timeliness: Report filed Jan 26, 2026 for a Jan 23 transaction (timely under Form 4 rules).
Context
This was an exercise of options followed by an immediate sale of the acquired shares (a common cashless or sell-to-cover pattern). Exercises convert derivative instruments into common shares (M), and the subsequent open-market sale (S) realized the gains; such transactions are typically routine and do not by themselves indicate the insider’s ongoing view of the company.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-01-23$140.85/sh+4,912$691,855→ 10,987.303 total - Exercise/Conversion
Common Stock
2026-01-23$132.58/sh+11,800$1,564,444→ 22,787.303 total - Sale
Common Stock
[F1]2026-01-23$279.77/sh−16,712$4,675,593→ 6,075.303 total - Exercise/Conversion
Stock Options (Right to Buy)
2026-01-23−4,912→ 0 totalExercise: $140.85From: 2021-02-06Exp: 2028-02-06→ Common Stock (4,912 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2026-01-23−11,800→ 9,016 totalExercise: $132.58From: 2023-02-04Exp: 2030-02-04→ Common Stock (11,800 underlying)
Footnotes (1)
- [F1]Represents the weighted average sales price for increments ranging from $279.60 to $280.25. The Reporting Person undertakes to provide upon request by the Securities and Exchange Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.